Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase 2 study of mFOLFIRINOX with or without stereotactic body radiotherapy in locally advanced pancreatic adenocarcinoma
KCT0005965Phase 2Active, not recruiting
- Sponsor
- Asan Medical Center
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mFOLFIRINOX in pancreatic adenocarcinoma (PDAC), sponsored by Asan Medical Center. Started Sep 2021; status: active, not recruiting.
02
Drugs
mFOLFIRINOX
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on KCT0005965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005965.